Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new injection help shed excess weight?

NCT ID NCT07745504

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This clinical trial is testing an investigational medicine called cagrilintide to see how well it helps people with overweight or obesity lose weight. Participants will receive either cagrilintide or a placebo (an inactive substance) by injection, and their weight change will be tracked over about 9 months. The study aims to compare two different presentations of cagrilintide to ensure they work similarly. Adults with a body mass index (BMI) of 27 or higher may be eligible to join.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cagrilintide
What this could lead to
If successful, this could support cagrilintide as a new treatment option for weight management in people with overweight or obesity.
What could go wrong
This is a Phase 3 trial, but results are not guaranteed. The medicine may not lead to significant weight loss or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 285 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) greater than or equal to (\>=) 30.0 kilograms per square meter (kg/m\^2), or BMI \>= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. Exclusion criteria: * History of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D). * Previous dosing of marketed or non-marketed amylin-based compounds. * Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    36 sites in 6 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • APDP - Associação Protectora dos Diabéticos de Portugal

    RECRUITING

    Lisbon, 1250-189, Portugal

  • Athens Medical Center S.A. (Iatriko Peristeriou) - Diabetes, obesity and cardiometabolic diseases department

    RECRUITING

    Peristeri, 121 31, Greece

  • Borbánya Praxis E.Ü. Kft.

    RECRUITING

    Nyíregyháza, Szabolcs-Szatmar Varmegye, 4405, Hungary

  • CVP Hospital Cruz Vermelha_Cardiologia

    RECRUITING

    Lisbon, 1549-008, Portugal

  • Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.

    RECRUITING

    Novi Sad, 21000, Serbia

  • Clinical Centre Nis, Endocrinology, Diabetes and Metabolism

    RECRUITING

    Niš, 18000, Serbia

  • Coastal Carolina Res Ctr

    RECRUITING

    North Charleston, South Carolina, 29405, United States

  • Dalecarlia Clinical Research AB

    RECRUITING

    Rättvik, 795 30, Sweden

  • East West Med Res Inst

    RECRUITING

    Honolulu, Hawaii, 96814, United States

  • Endocrinology, Diabetes and Metabolism Diseases Clinic

    RECRUITING

    Belgrade, 11000, Serbia

  • Forsåker vårdcentral

    RECRUITING

    Mölndal, 431 33, Sweden

  • General Hospital Of Athens Alexandra - Department of Endocrinology, Diabetes Center

    RECRUITING

    Athens, 115 28, Greece

  • General Hospital Of Athens G Gennimatas - Department of Endocrinology

    RECRUITING

    Athens, 11527, Greece

  • General Hospital Venizeleio-Pananeio - Diabetic Clinic

    RECRUITING

    Irakleio, 71409, Greece

  • Health Res of Hampton Roads

    RECRUITING

    Newport News, Virginia, 23606, United States

  • Hope Clin Res & Wellness

    RECRUITING

    Conyers, Georgia, 30094, United States

  • Hospital São Francisco, S.A_EECC

    RECRUITING

    Leiria, 2400-110, Portugal

  • Institute for Cardiovascular Diseases of Vojvodina - Sremska Kamenica

    RECRUITING

    Kamenitz, 21204, Serbia

  • Ippokratio General Hospital Of Thessaloniki - B' Internal Medicine clinic

    RECRUITING

    Thessaloniki, 546 42, Greece

  • KDCILM, LLC & Accellacare US, Inc.

    RECRUITING

    Wilmington, North Carolina, 28401, United States

  • KomplexLabor Diagnosztika Kft.

    RECRUITING

    Szeged, 6724, Hungary

  • Midwest Inst For Clin Res

    RECRUITING

    Indianapolis, Indiana, 46260, United States

  • National Clin Res Inc.

    RECRUITING

    Richmond, Virginia, 23294, United States

  • PharmQuest

    RECRUITING

    Greensboro, North Carolina, 27408, United States

  • Selma Medical Associates

    RECRUITING

    Winchester, Virginia, 22601-3834, United States

  • Skånes Universitets Sjukhus

    RECRUITING

    Lund, 222 42, Sweden

  • St. Luke's Hospital S.A. - Endocrinology Department and Obesity Clinic

    RECRUITING

    Thessaloniki, 552 36, Greece

  • Stúdium Egészségház Kft.

    RECRUITING

    Kalocsa, Bács-Kiskun county, 6300, Hungary

  • The Alliance for Multispecialty Research LLC AMR

    RECRUITING

    Lexington, Kentucky, 40509, United States

  • Trial Pharma Kft.

    RECRUITING

    Kecskemét, 6000, Hungary

  • ULS De Gaia/Espinho_H.Santos Silva_Endocrinologia

    RECRUITING

    Vila Nova de Gaia, 4434-502, Portugal

  • ULS Do Baixo Mondego, E.P.E. - HDFF_Serviço Cirurgia (Esp. Endocrinologia)

    RECRUITING

    Figueira da Foz Municipality, 3094-001, Portugal

  • ULS Do Oeste E.P.E. - Unidade Caldas da Rainha_CAMI - Unidade de Diabetes

    RECRUITING

    Caldas da Rainha, 2500-176, Portugal

  • University Clinical Centre Nis, Clinic for Cardiology

    RECRUITING

    Niš, 18108, Serbia

  • Walgreens - Store 11760

    NOT_YET_RECRUITING

    Oak Park, Illinois, 60302, United States

  • Örebro US - Överviktsenheten

    RECRUITING

    Örebro, 701 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.